Literature DB >> 16599827

Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay.

Aldo Clerico1, Gian Carlo Zucchelli, Alessandro Pilo, Claudio Passino, Michele Emdin.   

Abstract

The clinical relevance of brain natriuretic peptide (BNP) and N-terminal (NT)-proBNP assays as a diagnostic tool and prognostic marker in patients with cardiovascular diseases has recently been confirmed. However, several studies demonstrated variation of intra-individual BNP concentrations of >30% (ranging from 30% to 50%) with reference change values at the 95% confidence interval (i.e., the estimated critical difference) ranging from 99% to 130% in healthy subjects and heart failure patients. According to this estimated confidence interval, only a great variation in plasma BNP levels should be considered significant in an individual patient (for example, a decrease of >50% or an increase of more than two-fold). Many recent clinical studies have demonstrated that BNP variations below this estimated critical difference could also have clinical relevance. Like the concentration of other neuro-hormones, levels of plasma BNP fluctuate widely and rapidly along with heart rhythm and blood pressure variations in response to physiological stimuli. However, biological variation of BNP should not be interpreted strictly as random fluctuation around a homeostatic set point, as assumed by the common model used in all studies on biological variation of BNP reported in the literature. These results cannot be directly transferred to clinical practice. While awaiting more accurate studies, we suggest that variations of plasma BNP three-fold greater than the analytical imprecision should be considered as potentially relevant from a physiological and clinical point of view.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16599827     DOI: 10.1515/CCLM.2006.063

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  11 in total

1.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Authors:  Mariell Jessup; Barry Greenberg; Donna Mancini; Thomas Cappola; Daniel F Pauly; Brian Jaski; Alex Yaroshinsky; Krisztina M Zsebo; Howard Dittrich; Roger J Hajjar
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

Review 2.  Corin: A Key Mediator in Sodium Homeostasis, Vascular Remodeling, and Heart Failure.

Authors:  Xianrui Zhang; Xiabing Gu; Yikai Zhang; Ningzheng Dong; Qingyu Wu
Journal:  Biology (Basel)       Date:  2022-05-07

Review 3.  Natriuretic Peptides and Troponins to Predict Cardiovascular Events in Patients Undergoing Major Non-Cardiac Surgery.

Authors:  Marco Alfonso Perrone; Alberto Aimo; Sergio Bernardini; Aldo Clerico
Journal:  Int J Environ Res Public Health       Date:  2022-04-24       Impact factor: 4.614

4.  N-terminal pro-brain natriuretic peptide (NT-proBNP) release in children with vagus nerve stimulation. A prospective case series.

Authors:  Markus Rauchenzauner; Edda Haberlandt; Martin Ortler; Tobias Tatarczyk; Markus Laimer; Eugen Trinka; Gerhard Luef
Journal:  J Neurol       Date:  2008-06-27       Impact factor: 4.849

5.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Authors:  Brian E Jaski; Mariell L Jessup; Donna M Mancini; Thomas P Cappola; Daniel F Pauly; Barry Greenberg; Kenneth Borow; Howard Dittrich; Krisztina M Zsebo; Roger J Hajjar
Journal:  J Card Fail       Date:  2009-04       Impact factor: 5.712

Review 6.  The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.

Authors:  Massimiliano Cantinotti; Yuk Law; Simona Vittorini; Maura Crocetti; Marotta Marco; Bruno Murzi; Aldo Clerico
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

7.  N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.

Authors:  Johannes Schnorbach; Hanna Fröhlich; Tobias Täger; Anna Corletto; Hugo A Katus; Lutz Frankenstein
Journal:  ESC Heart Fail       Date:  2019-07-01

8.  Perioperative application of N-terminal pro-brain natriuretic peptide in patients undergoing cardiac surgery.

Authors:  Hua Liu; Chunsheng Wang; Lan Liu; Yamin Zhuang; Xiaomei Yang; Ying Zhang
Journal:  J Cardiothorac Surg       Date:  2013-01-07       Impact factor: 1.637

9.  Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations.

Authors:  Trevor Simard; Richard Jung; Alisha Labinaz; Mohammad Ali Faraz; F Daniel Ramirez; Pietro Di Santo; Dylan Perry-Nguyen; Ian Pitcher; Pouya Motazedian; Chantal Gaudet; Rebecca Rochman; Jeffrey Marbach; Paul Boland; Kiran Sarathy; Saleh Alghofaili; Juan J Russo; Etienne Couture; Steven Promislow; Rob S Beanlands; Benjamin Hibbert
Journal:  J Am Heart Assoc       Date:  2019-08-05       Impact factor: 5.501

10.  Acute on chronic heart failure-Which variations on B-type natriuretic peptide levels?

Authors:  Paulo Bettencourt; Inês Chora; Filipa Silva; Patrícia Lourenço; W Frank Peacock
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.